Apimeds Pharmaceuticals US, Inc
APUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $0 | $2 | $0 | $0 |
| SG&A Expenses | $1 | $2 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $0 | $0 |
| Operating Income | -$2 | -$3 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$3 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS | -0.14 | -0.26 | -0.035 | -0.027 |
| % Growth | 46.2% | -647.1% | -28.9% | – |
| EPS Diluted | -0.14 | -0.26 | -0.035 | -0.025 |
| Weighted Avg Shares Out | 13 | 10 | 12 | 12 |
| Weighted Avg Shares Out Dil | 13 | 10 | 12 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$0 | -$0 |
| % Margin | – | – | – | – |